RATIONALE: Studying the long-term effects of cancer treatment in cancer survivors may help improve the ability to plan effective treatment and follow-up care.

PURPOSE: This phase II trial is studying the long-term effects of iodine I 131 tositumomab and autologous bone marrow or stem cell transplantation in patients with relapsed or refractory non-Hodgkin's lymphoma.

Condition	Treatment or Intervention	Phase
adult lymphomatoid granulomatosis adult non-Hodgkin's lymphoma indolent or aggressive adult non-Hodgkin's lymphoma Quality of Life	Procedure: complications of therapy assessment/management  Procedure: quality-of-life assessment  Procedure: supportive care/therapy	Phase II

Further Study Details: 

OBJECTIVES:

• Determine the progression-free survival and overall survival of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma previously treated with iodine I^131 tositumomab followed by autologous bone marrow or stem cell transplantation on FHCRC protocols 296, 521, 792, or 915.
• Determine the long-term toxic effects of this regimen in these patients.
• Determine the quality of life of patients treated with this regimen.

OUTLINE: This is a long-term, follow-up study.

Patients undergo physical examinations, blood tests, and immune system assessments every 3 months for 1 year and then annually thereafter. Thyroid, pulmonary, and cardiac function are assessed at 1 year and then annually as needed. Patients also undergo CT scans and bone marrow biopsy (if clinically indicated) annually for up to 10 years.

Quality of life is assessed annually.

PROJECTED ACCRUAL: A total of 47 patients will be accrued for this study.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of B-cell non-Hodgkin's lymphoma
• Relapsed or refractory disease
• Previously treated with myeloablative doses of iodine I
• tositumomab and autologous bone marrow or stem cell transplantation on 1 of the following phase I or II protocols:
• FHCRC-296
• FHCRC-521
• FHCRC-915

PATIENT CHARACTERISTICS: Age

• 18 and over

Performance status

• Not specified

Life expectancy

• Not specified

Hematopoietic

• Not specified

Hepatic

• Not specified

Renal

• Not specified

PRIOR CONCURRENT THERAPY: Biologic therapy

• See Disease Characteristics

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• See Disease Characteristics

Surgery

• Not specified

Washington
      Fred Hutchinson Cancer Research Center, Seattle,  Washington,  98109-1024,  United States; Recruiting

Study chairs or principal investigators

Oliver W. Press, MD, PhD,  Principal Investigator,  Fred Hutchinson Cancer Research Center   

Study ID Numbers:  CDR0000398806; FHCRC-1734.00; NCT00098566
Record last reviewed:  November 2004
Last Updated:  February 4, 2005
Record first received:  December 7, 2004
ClinicalTrials.gov Identifier:  NCT00098566
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08